Showing 7341-7350 of 8649 results for "".
- NPR Report: He and His Wife Both Got Cataract Surgery. His Bill Was 20 times Higher Than Hershttps://modernod.com/news/npr-report-he-and-his-wife-both-got-cataract-surgery-his-bill-was-20-times-higher-than-hers/2480934/A NPR report shares an example of the factors involved in how insurance companies determine reimbursement for cataract surgery. The articl
- Vision Expo West 2022 Opens Hotel Reservationshttps://modernod.com/news/vision-expo-west-2022-opens-hotel-reservations/2480917/The Vision Council and RX, co-organizers of Vision Expo, announced that reservations are now being accepted at Vision Expo West’s partner hotels for
- University of Wisconsin Eye Research Uncovers How Stem Cell Photoreceptors Reach Their Targetshttps://modernod.com/news/uw-eye-research-uncovers-how-stem-cell-photoreceptors-reach-their-targets/2480915/A new study reveals how photoreceptors grown from stem cells might extend biological wires, known as axons, to contact existing neurons. The finding has implications for future treatment of retinal diseases that cause blindness, including age-related macular degeneration (AMD) and rare disea
- New Study Shows Intraocular Lens Centration and Stability May Be Improved When Zepto Capsulotomy Platform is Used with Purkinje Reflectionshttps://modernod.com/news/new-study-shows-intraocular-lens-centration-and-stability-may-be-improved-when-zepto-capsulotomy-platform-is-used-with-purkinje-reflections/2480912/Centricity Vision announced the publication of a clinical study describing how to use Purkinje reflections at patient fixation for capsulotomy centration and 360-degree capsular overlap with the Zepto platform to help achieve improved visual outcomes. Published in the Journal
- NIH Researchers Discover New Genetic Eye Diseasehttps://modernod.com/news/nih-researchers-discover-new-genetic-eye-disease/2480909/Researchers from the National Eye Institute (NEI) have identified a new disease that affects the macula. Scientists report their findings on the novel macular dystrophy, which is yet to be named, in JAMA Ophthalmology. Macular dystrophies are disorders that usually cause central visual l
- Nicox Now Expects Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial in November 2022https://modernod.com/news/nicox-now-expects-topline-results-from-ncx-470-mont-blanc-phase-3-glaucoma-trial-in-november-2022/2480892/Nicox SA announced that it has closed screening for additional patients in its phase 3 Mont Blanc clinical trial of NCX 470 0.1% in patients with open-angle glaucoma or ocular hypertension. Therefore, the company now expects
- Oertli Expands its Direct Distribution Networkhttps://modernod.com/news/oertli-expands-its-direct-distribution-network/2480889/Oertli Instrumente acquired the Swiss distributor Domedics AG and integrated the company as of June 1 into their global brand. Terms of the deal were not disclosed. In September 2021, Oertli Instrumente took over the majority of shares in Domedics, a Switzerland-base
- Market Scope: Global PC-IOL Demand Rises Modestly, Soars in a Few Countrieshttps://modernod.com/news/market-scope-global-pc-iol-demand-rises-modestly-soars-in-a-few-countries/2480888/Presbyopia-correcting IOLs experienced steady global growth in 2021 and record-breaking growth in a handful of countries, according to a Market Scope re
- Newly Published 12-Month Clinical Data for Sight Sciences’ Omni Surgical Systemhttps://modernod.com/news/newly-published-12-month-clinical-data-for-sight-sciences-omni-surgical-system/2480887/Sight Sciences announced publication in
- Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101https://modernod.com/news/qlaris-bio-reports-phase-2-clinical-trial-results-demonstrating-favorable-safety-and-tolerability-profile-and-positive-efficacy-signal-for-qls-101/2480871/Qlaris Bio announced results from QC-201, a first-in-human, phase 2 clinical trial of QLS-101, the company’s investigational therapy for lowering IOP in the treatment of glaucoma. Study findings demonstrated a favorable safety and tolerability profile for QLS-101, including no evi